Effective bleed protection
Proven bleed protection across all ages and clinical settings, including acute bleed control and perioperative management.4–8
Positive long-term joint outcomes
Sustained joint protection across all ages, backed by 6.5 years cumulative clinical trial experience.4
Well-established safety profile
Backed by clinical and real-world data.4,9
Extensive experience
Robust clinical data, supported by >10 years of real-world experience.1
Fc fusion technology
Extending the half-life of FIX via the natuaral recycling pathway.5,6
References
1. ALPROLIX Package Insert. FDA. Revised May 2023. 2. Rebinyn Package Insert. FDA. Revised August 2022. 3. Idelvion Package Insert. FDA. Revised June 2023. 4. Shapiro A, et al. Blood Adv. 2023;7(13):3049–3057. 5. ALPROLIX UK Summary of Product Characteristics. 6. ALPROLIX EU Summary of Product Characteristics. 7. Chowdary P, et al. Res Pract Thromb Haemost. 2022;6(5):e12760. 8. Nolan B, et al. Blood Adv. 2021;5(13):2732–2739. 9. Chambost H, et al. Ther Adv Hematol. 2025:16;1–15.
ALPROLIX is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). ALPROLIX can be used for all age groups.5,6
Adverse events should be reported. Reporting forms and information can be found, for United Kingdom: via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. For Ireland: via HPRA Pharmacovigilance website www.hpra.ie. Adverse events should also be reported to Swedish Orphan Biovitrum Ltd by email at [email protected] or by calling +44 (0) 800 111 4754.